FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer
作者
Kathleen N. Moore,Ignace B. Vergote,Ana Oaknin,Nicoletta Colombo,Susana N. Banerjee,Amit M. Oza,Patricia Pautier,Catherine Margaret Kelly,Karim S. Malek,Michael J. Birrer
PDF的下载单位、IP信息已删除
(2025-6-4)
null
嘻嘻哈哈
ZDN03
学霸业
Nole
渡人舟
GingerF
auqkhter
Criminology34
看不了一点文献
taojqtony
Elsevier大王
无极微光
果果123
v0id
吃葡萄不吐葡萄皮
强健的面包
血癌乌鸦
sanvva
prigogin
皖公网安备34019202002308
